美国阿兹海默症诊断市场规模、份额、趋势分析报告（按诊断技术、类型、最终用途、细分市场预测），2025-2030 年

市场规模与趋势：

美国阿兹海默症诊断市场规模预计在2024年达到35.3亿美元，2025年至2030年的复合年增长率为10.6%。这一增长主要源于阿兹海默症的疾病上升以及对早期准确诊断的日益重视。根据美国疾病管制与预防中心 (CDC) 的数据，到2024年，美国将有约670万老年人罹患阿兹海默症，预计到2060年这一数字将增加近一倍。阿兹海默症患者病率的上升促使各国政府和私人医疗机构大力投资PET影像、脑脊髓液生物标记和血液诊断等先进诊断技术。

美国阿兹海默症诊断市场的成长得益于近期先进非侵入性诊断技术的核准。美国食品药物管理局 (FDA) 已批准首款透过血液检测辅助诊断阿兹海默症的体外诊断设备上市。 Lumipulse G pTau217/B-淀粉样蛋白 1-42 血浆比例旨在早期检测淀粉样斑块的形成，这是阿兹海默症病理学的一个标誌，特别适用于 55 岁及以上、出现与认知障碍相符临床症状和体征的成年患者。

这项进展标誌着阿兹海默症诊断领域的重大进步，并透过提供一种经济高效、微创的PET扫描和脊椎穿刺替代方案，显着降低了诊断门槛。 FDA强调，此次核准可能使美国患者能够更早、更轻鬆、更方便地接受检测。这凸显了该检测在促进阿兹海默症早期进展中及时干预和临床决策方面的价值。

老年人失智症诊断率的上升正在推动美国阿兹海默症诊断市场的成长。根据美国疾病管制与预防中心 (CDC) 2022 年的全国健康访问调查，约有 4% 的 65 岁及以上人群被诊断患有失智症，而 85 岁及以上人群的这一数字则上升至 13%。这一增长主要得益于预期寿命的延长、认知度的提高以及临床诊断方法的改善。这推动了对扩充性、准确的诊断解决方案的需求，这些解决方案可支援早期发现、适当的干预和优化的护理计划。

目录

第一章调查方法与范围

第二章执行摘要

第三章美国阿兹海默症诊断市场变数、趋势和范围

• 市场展望
• 市场动态
  • 市场驱动因素分析
  • 市场限制因素分析
  • 产业挑战
• 产业分析工具
  • 波特分析
  • PESTEL分析

第四章美国阿兹海默症诊断市场：诊断技术评估与趋势分析

• 美国阿兹海默症诊断市场（按诊断技术）：关键要点
• 2024 年及 2030 年诊断技术趋势分析及市场占有率
• 按诊断技术，2018-2030 年
  • 生物标誌物
  • 诊断影像技术
  • 基因检测
  • 认知评估测试

第五章美国阿兹海默症诊断市场：类型估计和趋势分析

• 美国阿兹海默症诊断市场（按类型）：关键要点
• 2024 年和 2030 年类型趋势分析和市场占有率
• 按类型，2018-2030
  • 分类
  • 诊断
  • 筛检

第六章美国阿兹海默症诊断市场：最终用途估计与趋势分析

• 美国阿兹海默症诊断市场（按最终用途划分）：关键要点
• 2024 年和 2030 年最终用途变化分析和市场占有率
• 按应用，2018-2030 年
  • 医院
  • 诊断实验室
  • 学术研究所

第七章 竞争态势

• 公司分类
• 公司市场定位
• 公司热图分析
• 公司简介/上市公司
  • GE HealthCare
  • Siemens Healthineers AG
  • Canon Medical Systems Corporation
  • Cerveau Technologies, Inc.
  • Neurovision Imaging, Inc.
  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories, Inc.
  • Quanterix Corporation
  • Alzheon Inc.
  • NanoSomiX, Inc.
  • DiamiR Biosciences

Market Size & Trends:

The U.S. Alzheimer's disease diagnostics market was valued at USD 3.53 billion in 2024 and is expected to grow at a CAGR of 10.6% from 2025 to 2030. This growth is driven by the rising prevalence of Alzheimer's disease and increasing emphasis on early and accurate diagnosis. According to the U.S. Centers for Disease Control and Prevention (CDC), approximately 6.7 million older adults in the U.S. were living with Alzheimer's disease in 2024, a number projected to nearly double by 2060. The growing prevalence of the disease prompted government and private healthcare bodies to invest heavily in advanced diagnostic technologies such as PET imaging, cerebrospinal fluid biomarkers, and blood-based diagnostics.

The growth of the U.S. Alzheimer's disease diagnostics market is due to the recent regulatory approval of advanced, non-invasive diagnostic technologies. The U.S. FDA granted marketing clearance for the first in vitro diagnostic device that utilizes a blood test to support the diagnosis of Alzheimer's disease. The Lumipulse G pTau217/B-Amyloid 1-42 Plasma Ratio is specifically intended for the early detection of amyloid plaque accumulation, a hallmark of Alzheimer's pathology, in adult patients aged 55 years and older who are exhibiting clinical signs and symptoms consistent with cognitive impairment.

This development represents a major advancement in Alzheimer's diagnostics, significantly lowering access barriers by providing a cost-effective and minimally invasive alternative to PET scans and lumbar punctures, which often carry procedural risks. The FDA highlighted that this approval makes it easier and potentially more accessible for U.S. patients earlier in the disease. It underscores the test's value in facilitating timely intervention and clinical decision-making in the early stages of Alzheimer's disease progression.

The increasing rate of dementia diagnosis among older adults is driving the growth of the U.S. Alzheimer's diagnostics market. According to the 2022 National Health Interview Survey by the CDC, approximately 4% of individuals aged 65 and older have been diagnosed with dementia, with this figure rising to 13% among those aged 85 and above. This growth is primarily attributed to longer life expectancy, enhanced awareness, and improved diagnostic practices across clinical settings. The rising need for scalable, accurate diagnostic solutions to support early detection, appropriate intervention, and optimized care planning.

U.S. Alzheimer's Disease Diagnostics Market Report Segmentation

This report forecasts revenue growth at the country level and analyzes the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. Alzheimer's disease diagnostics market report based on diagnostic technique, type, and end-use:

• Diagnostic Technique Outlook (Revenue, USD Million, 2018 - 2030)
• Biomarkers
  • CSF Biomarkers
  • Blood-Based Biomarkers
• Imaging Diagnostic Techniques
• Genetic Testing
• Cognitive Assessment Tests
• Type Outlook (Revenue, USD Million, 2018 - 2030)
• Triage
• Diagnosis
• Screening
• End Use Outlook (Revenue, USD Million, 2018 - 2030)
• Hospitals
• Diagnostic Laboratories
• Academic & Research Institutes

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1. Purchased Database
  • 1.3.2. GVR's Internal Database
  • 1.3.3. Secondary Sources and Third-Party Perspectives
  • 1.3.4. Primary Research
• 1.4. Information Analysis
  • 1.4.1. Data Analysis Models
• 1.5. Market Formulation and Data Visualization
• 1.6. Data Validation and Publishing

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Alzheimer's Disease Diagnostics Market Variables, Trends and Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
  • 3.2.3. Industry Challenge
• 3.3. Industry Analysis Tools
  • 3.3.1. PORTER's Analysis
    • 3.3.1.1. Bargaining power of the suppliers
    • 3.3.1.2. Bargaining power of the buyers
    • 3.3.1.3. Threats of substitution
    • 3.3.1.4. Threats from new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and social landscape
    • 3.3.2.3. Technological landscape

Chapter 4. U.S. Alzheimer's Disease Diagnostics Market: Diagnostic Technique Estimates and Trend Analysis

• 4.1. U.S. Alzheimer's Disease Diagnostics Market, By Diagnostic Technique: Key Takeaways
• 4.2. Diagnostic Technique Movement Analysis and Market Share, 2024 and 2030
• 4.3. Market Estimates and Forecasts, By Diagnostic Technique, 2018 - 2030 (USD Million)
  • 4.3.1. Biomarkers
    • 4.3.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.1.2. CSF Biomarkers
      • 4.3.1.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.1.3. Blood-Based Biomarkers
      • 4.3.1.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.3.2. Imaging Diagnostic Techniques
    • 4.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.3.3. Genetic Testing
    • 4.3.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.3.4. Cognitive Assessment Tests
    • 4.3.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Alzheimer's Disease Diagnostics Market: Type Estimates and Trend Analysis

• 5.1. U.S. Alzheimer's Disease Diagnostics Market, By Type: Key Takeaways
• 5.2. Type Movement Analysis and Market Share, 2024 and 2030
• 5.3. Market Estimates and Forecasts, By Type, 2018 - 2030 (USD Million)
  • 5.3.1. Triage
    • 5.3.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.2. Diagnosis
    • 5.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.3. Screening
    • 5.3.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Alzheimer's Disease Diagnostics Market: End Use Estimates and Trend Analysis

• 6.1. U.S. Alzheimer's Disease Diagnostics Market, By End Use: Key Takeaways
• 6.2. End Use Movement Analysis and Market Share, 2024 and 2030
• 6.3. Market Estimates and Forecasts, By End Use, 2018 - 2030 (USD Million)
  • 6.3.1. Hospitals
    • 6.3.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.2. Diagnostic Laboratories
    • 6.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.3. Academic and Research Institutes
    • 6.3.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company Categorization
• 7.2. Company Market Positioning
• 7.3. Company Heat Map Analysis
• 7.4. Company Profiles/Listing
  • 7.4.1. GE HealthCare
    • 7.4.1.1. Company Overview
    • 7.4.1.2. Financial Performance
    • 7.4.1.3. Diagnostic Technique Portfolio
    • 7.4.1.4. Recent Developments/ Strategic Initiatives
  • 7.4.2. Siemens Healthineers AG
    • 7.4.2.1. Company Overview
    • 7.4.2.2. Financial Performance
    • 7.4.2.3. Diagnostic Technique Portfolio
    • 7.4.2.4. Recent Developments/ Strategic Initiatives
  • 7.4.3. Canon Medical Systems Corporation
    • 7.4.3.1. Company Overview
    • 7.4.3.2. Financial Performance
    • 7.4.3.3. Diagnostic Technique Portfolio
    • 7.4.3.4. Recent Developments/ Strategic Initiatives
  • 7.4.4. Cerveau Technologies, Inc.
    • 7.4.4.1. Company Overview
    • 7.4.4.2. Financial Performance
    • 7.4.4.3. Diagnostic Technique Portfolio
    • 7.4.4.4. Recent Developments/ Strategic Initiatives
  • 7.4.5. Neurovision Imaging, Inc.
    • 7.4.5.1. Company Overview
    • 7.4.5.2. Financial Performance
    • 7.4.5.3. Diagnostic Technique Portfolio
    • 7.4.5.4. Recent Developments/ Strategic Initiatives
  • 7.4.6. Thermo Fisher Scientific Inc.
    • 7.4.6.1. Company Overview
    • 7.4.6.2. Financial Performance
    • 7.4.6.3. Diagnostic Technique Portfolio
    • 7.4.6.4. Recent Developments/ Strategic Initiatives
  • 7.4.7. Bio-Rad Laboratories, Inc.
    • 7.4.7.1. Company Overview
    • 7.4.7.2. Financial Performance
    • 7.4.7.3. Diagnostic Technique Portfolio
    • 7.4.7.4. Recent Developments/ Strategic Initiatives
  • 7.4.8. Quanterix Corporation
    • 7.4.8.1. Company Overview
    • 7.4.8.2. Financial Performance
    • 7.4.8.3. Diagnostic Technique Portfolio
    • 7.4.8.4. Recent Developments/ Strategic Initiatives
  • 7.4.9. Alzheon Inc.
    • 7.4.9.1. Company Overview
    • 7.4.9.2. Financial Performance
    • 7.4.9.3. Diagnostic Technique Portfolio
    • 7.4.9.4. Recent Developments/ Strategic Initiatives
  • 7.4.10. NanoSomiX, Inc.
    • 7.4.10.1. Company Overview
    • 7.4.10.2. Financial Performance
    • 7.4.10.3. Diagnostic Technique Portfolio
    • 7.4.10.4. Recent Developments/ Strategic Initiatives
  • 7.4.11. DiamiR Biosciences
    • 7.4.11.1. Company Overview
    • 7.4.11.2. Financial Performance
    • 7.4.11.3. Diagnostic Technique Portfolio
    • 7.4.11.4. Recent Developments/ Strategic Initiatives

List of Tables

• Table 1 List of abbrevation
• Table 2 U.S. alzheimer's disease diagnostics market: key market driver analysis
• Table 3 U.S. alzheimer's disease diagnostics market: Key market restraint analysis
• Table 4 U.S. alzheimer's disease diagnostics market estimates and forecast, by diagnostic technique (USD Million)
• Table 5 U.S. alzheimer's disease diagnostics market estimates and forecast, by type (USD Million)
• Table 6 U.S. alzheimer's disease diagnostics market estimates and forecast, by end use (USD Million)
• Table 7 Recent developments and impact analysis by key market participants
• Table 8 Company heat map analysis, 2024
• Table 9 Companies implementing key strategies

List of Figures

• Fig. 1 U.S. Alzheimer's disease diagnostics market segmentation
• Fig. 2 Market research process
• Fig. 3 Information procurement
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value chain-based sizing and forecasting
• Fig. 7 Parent market analysis
• Fig. 8 Market formulation and validation
• Fig. 9 U.S. Alzheimer's disease diagnostics market snapshot
• Fig. 10 U.S. Alzheimer's disease diagnostics market segment snapshot
• Fig. 11 U.S. Alzheimer's disease diagnostics market competitive landscape snapshot
• Fig. 12 Market research process
• Fig. 13 Market driver relevance analysis (Current and future impact)
• Fig. 14 Market restraint relevance analysis (Current and future impact)
• Fig. 15 U.S. Alzheimer's disease diagnostics market: Diagnostic technique outlook key takeaways (USD Million)
• Fig. 16 U.S. Alzheimer's disease diagnostics market: Diagnostic technique movement analysis 2024 & 2030 (USD Million)
• Fig. 17 Biomarkers market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 18 Imaging diagnostic Techniques market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 19 Genetic testing market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 20 Cognitive assessment tests market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 21 U.S. Alzheimer's Disease Diagnostics market: Type outlook key takeaways (USD Million)
• Fig. 22 U.S. Alzheimer's Disease Diagnostics market: Type movement analysis 2024 & 2030 (USD Million)
• Fig. 23 Triage market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 24 Diagnosis market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 25 Screening market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 26 U.S. alzheimer's disease diagnostics market: End Use outlook key takeaways (USD Million)
• Fig. 27 U.S. alzheimer's disease diagnostics market: End Use movement analysis 2024 & 2030 (USD Million)
• Fig. 28 Hospitals market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 29 Diagnostic Laboratories market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 30 Academic and Research Institutes market estimates & forecasts, 2018 - 2030 (USD Million)
• Fig. 31 Strategy framework
• Fig. 32 Company categorization